care

New combinations promote individualized bladder and prostate cancer care

Investigational combinations, such as androgen deprivation therapy (ADT) plus lutetium 177 (177Lu) PSMA-617 (177Lu-PSMA-617) and androgen receptor (AR) signaling inhibitors in prostate cancer and sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) in urothelial carcinoma, may open up increasingly specific treatment options, according to Alicia Morgans, MD, MPH. “During [advances in these fields] it requires continuous learning …

New combinations promote individualized bladder and prostate cancer care Read More »

A new combination of drugs and chemotherapy could offer a ‘new standard of care’ for certain types of digestive system cancer

Zolbetuximab plus mFOLFOX6—a chemotherapy combination commonly used in gastric cancer—significantly prolonged patients’ progression-free survival compared with mFOLFOX6 alone in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction ( GEJ) adenocarcinoma, according to primary phase 3 data from the SPOTLIGHT trial. The results, presented during the 2023 Gastrointestinal Cancer Symposium, a conference organized …

A new combination of drugs and chemotherapy could offer a ‘new standard of care’ for certain types of digestive system cancer Read More »